In early January 2024, Merck announced the acquisition of Harpoon, which is expected to close in the first half of 2024, and result in a non-tax deductible charge of approximately $650M of R&D expense included in non-GAAP results. The impact of the transaction on expected full-year non-GAAP EPS is approximately 26c per share, which is included in the 2024 outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- Senate Health, Education, Labor & Pensions Committee holds an executive session
- MRK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Merck price target raised to $127 from $116 at Morgan Stanley
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Merck’s KEYTRUDA reduced risk of death by 38% as adjuvant therapy in RCC
Questions or Comments about the article? Write to editor@tipranks.com